Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio Files to Begin Trial of Anemia Drug

publication date: Jan 8, 2010
3SBio Inc. applied to the SFDA to begin a registrational clinical trial for Feraheme™ (ferumoxytol) Injection, an IV treatment for iron deficiency anemia in patients with chronic kidney disease. 3SBio licensed the China rights for the drug from AMAG Pharmaceuticals last May, shortly before AMAG was granted approval for the product by the US FDA. More details...

Stock Symbols: (NSDQ: SSRX) (NSDQ: AMAG)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital